More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$891389134
EPS
-0.35
P/E ratio
--
Price to sales
2.2
Dividend yield
--
Beta
1.301815
Previous close
$18.47
Today's open
$18.19
Day's range
$18.13 - $18.68
52 week range
$18.12 - $48.25
show more
CEO
J. Patrick Mackin
Employees
1800
Headquarters
Kennesaw, GA
Exchange
New York Stock Exchange
Shares outstanding
48789772
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Artivion Q3 Earnings Call Highlights
Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.
MarketBeat • Nov 7, 2026

Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Artivion Reports Third Quarter 2026 Financial Results
Third Quarter & Recent Business Highlights: Achieved revenue of $123.8 million in the third quarter of 2026 versus $113.4 million in the third quarter of 2025, an increase of 9% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the third quarter of 2026 was $(7.9) million, or $(0.16) per fully diluted share, and non-GAAP net income was $3.8 million, or $0.08 per fully diluted share Adjusted EBITDA declined 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. "In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.
PRNewsWire • Nov 5, 2026

Artivion (AORT) Lags Q3 Earnings Estimates
Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Artivion to Participate in Upcoming Investor Conferences
ATLANTA, Oct. 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at the Lotte New York Palace Hotel.
PRNewsWire • Oct 28, 2026

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
PRNewsWire • Oct 22, 2026

Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update
Class A shares of the Alger Dynamic Opportunities Fund outperformed the S&P 500 Index during the second quarter of 2026. For the quarter, the portfolio's average long exposure was 88.77% and the average short exposure was -37.38%. Long positions Nebius Group, Astera Labs, Inc., and Western Digital Corporation were among the top contributors to performance.
Seeking Alpha • Aug 9, 2026

Artivion Q2 Earnings Call Highlights
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
MarketBeat • Aug 7, 2026

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 7, 2026

Artivion Reports Second Quarter 2026 Financial Results
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
PRNewsWire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Artivion Inc Com commission-free¹. Build wealth for the long term using automated trading and transfers.